Market: NYQ |
Currency:
Address:
📈 RAC Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
-
-
Upside/Downside from Analyst Target:
-
-
Broker Call:
-
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
-
-
Net Income Growth Range (1Y):
-
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
-
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for RAC
No earnings history available for this symbol.
📰 Related News & Research
-
Anterix Inc. Announces New Contract and SEC Filing Details – Nasdaq Capital Market Listing and Company Information
April 6, 2026
Anterix Inc. Announces Milestone 900 MHz Spectrum Sale to No...
-
Oracle Appoints Hilary Maxson as Chief Financial Officer Amid Record Cloud Growth
April 6, 2026
Oracle Appoints Hilary Maxson as CFO During Period of Rapid ...
-
Cycurion Reports 2025 Financial Results: Cost Reductions, AI Investments, and $112M Contract Backlog Position Company for 2026 Growth
April 6, 2026
Cycurion, Inc. 2025 Full-Year Financial Results – Investor-F...
-
Interactive Strength Inc. 8-K Filing Details Material Definitive Agreement and Entity Information for March 31, 2026
April 4, 2026
Interactive Strength Inc. (NASDAQ: TRNR) Announces Settlemen...
-
Rackspace Technology, Inc. 8-K SEC Filing Details for March 31, 2026 – Company Information & Stock Data
April 4, 2026
Rackspace Technology, Inc. Announces Resignation of Board Me...
-
Anterix Inc. Files 8-K Announcing New Contract and Press Release with TNMP on Nasdaq Capital Market
April 1, 2026
Anterix Inc. Announces Spectrum Sale Agreement with Texas-Ne...
-
Sidus Space Reports 2025 Financial Results: Expands LizzieSat Fleet, Secures Major Defense Contracts, and Strengthens Balance Sheet
April 1, 2026
Sidus Space Inc. Full-Year 2025 Financial Results and Busine...
-
Inhibitor Therapeutics Advances Amorphous Itraconazole Formulation for Gorlin Syndrome With New Patent Filing and Clinical Milestones 12
April 1, 2026
Inhibitor Therapeutics Provides Key Update on Itraconazole P...
-
Allarity Therapeutics Reports 2025 Financial Results, Advances Stenoparib in Ovarian and Lung Cancer with FDA Fast Track Designation
April 1, 2026
Allarity Therapeutics 2025 Full Year Financial Results & Cor...
-
Darco Water Technologies Extends Tranche A Completion Date for 49% Acquisition of Darco InfraCo Vietnam Water to 21 April 2026
April 1, 2026
Darco Water Technologies Limited: Extension of Proposed Acqu...
🔍 View more Reports